{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:45:55Z","timestamp":1792183555753,"version":"4.4.0"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rivaroxaban use for inferior vena cava (IVC) thrombosis after successful catheter-directed thrombolysis (CDT) is rarely reported. This study aimed at investigating the safety and efficacy of rivaroxaban for IVC thrombosis after CDT. The clinical data on 38 consecutive patients with IVC thrombosis (68% male; mean age, 51.5\u2009\u00b1\u200916.5), who received rivaroxaban after CDT between July 2017 and January 2020, were retrospectively analyzed in this study. Safety and efficacy of rivaroxaban (bleedings and recurrent venous thromboembolism), cumulative prevalence of post-thrombotic syndrome (PTS), primary patency, clinically driven target lesion revascularization rate, and other adverse events including all-cause mortality and vascular events (systemic embolism, acute coronary syndrome, ischemic stroke, and transient ischemic attack) were retrospectively analyzed. Of the 38 patients who received rivaroxaban for IVC thrombosis after CDT, 27 (71%) had an anticoagulant duration of 6 months and 11 patients (29%) of more than 6 months. Four patients (10%) suffered recurrent thrombosis. No patient suffered major bleeding, while clinically relevant nonmajor bleeding occurred in two (5%) patients. The cumulative prevalence of PTS was 18% (7\/38) during the 12 months follow-up period. Primary patency at 1, 3, 6, and 12 months was 97, 92, 90, and 90%, respectively. According to follow-up data, the clinically driven target lesion revascularization of this study was 10%. Cardiovascular events and mortality did not occur in any patient during the study period. Rivaroxaban for IVC thrombosis after successful CDT can be safe and effective.<\/jats:p>","DOI":"10.1055\/s-0041-1733924","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T00:33:35Z","timestamp":1633826015000},"page":"459-464","source":"Crossref","is-referenced-by-count":5,"title":["Safety and Efficacy of Rivaroxaban for Inferior Vena Cava Thrombosis after Successful Catheter-Directed Thrombolysis"],"prefix":"10.1055","volume":"48","author":[{"given":"Jun","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"e001882","DOI":"10.1161\/CIRCINTERVENTIONS.114.001882","article-title":"Comparative outcomes of catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of inferior vena caval thrombosis","volume":"8","author":"M Alkhouli","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3949\/ccjm.84.s3.04","article-title":"Update on the management of venous thromboembolism","volume":"84","author":"J R Bartholomew","year":"2017","journal-title":"Cleve Clin J Med"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"J A Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.thromres.2007.06.009","article-title":"The MASTER registry on venous thromboembolism: description of the study cohort","volume":"121","author":"G Agnelli","year":"2008","journal-title":"Thromb Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"I4","DOI":"10.1161\/01.CIR.0000078468.11849.66","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"R H White","year":"2003","journal-title":"Circulation"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11239-006-5574-9","article-title":"The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis","volume":"21","author":"S R Kahn","year":"2006","journal-title":"J Thromb Thrombolysis"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.amjcard.2008.05.046","article-title":"Incidence of vena cava thrombosis in the United States","volume":"102","author":"P D Stein","year":"2008","journal-title":"Am J Cardiol"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jcin.2015.12.268","article-title":"Inferior Vena Cava Thrombosis","volume":"9","author":"M Alkhouli","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1358863X12471967","article-title":"Inferior vena cava thrombosis: a review of current practice","volume":"18","author":"B J McAree","year":"2013","journal-title":"Vasc Med"},{"issue":"43","key":"ref10","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism","volume":"35","author":"S V Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3400\/avd.ra.17-00015","article-title":"Novel anticoagulant therapy of venous thromboembolism: current status and future directions","volume":"10","author":"M Nakamura","year":"2017","journal-title":"Ann Vasc Dis"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1160\/TH14-06-0484","article-title":"Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism","volume":"113","author":"J Beyer-Westendorf","year":"2015","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","article-title":"Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment","volume":"41","author":"A E Burnett","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"26","key":"ref14","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"M H Prins","year":"2013","journal-title":"Thromb J"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"W Ageno","year":"2016","journal-title":"Lancet Haematol"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1253\/circj.CJ-18-1141","article-title":"Rivaroxaban for fully occlusive inferior vena cava filter thrombus","volume":"83","author":"A Sakatani","year":"2019","journal-title":"Circ J"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)61753-4","article-title":"Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial","volume":"379","author":"T Enden","year":"2012","journal-title":"Lancet"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's choice\u2014European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"S K Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.avsg.2015.04.076","article-title":"Catheter-directed therapy is safe and effective for the management of acute inferior vena cava thrombosis","volume":"29","author":"K H Nagarsheth","year":"2015","journal-title":"Ann Vasc Surg"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jvsv.2020.11.025","article-title":"Outcomes of Aspirex\u00aeS thrombectomy system combined with catheter-directed thrombolysis for treating bilateral lower extremity deep venous thrombosis","volume":"9","author":"M Nie","year":"2021","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"20356","DOI":"10.1038\/s41598-019-56887-w","article-title":"Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial","volume":"9","author":"J M Kang","year":"2019","journal-title":"Sci Rep"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"21","key":"ref26","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2015.09.063","article-title":"Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA","volume":"66","author":"J R Laird","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jcpt.12552","article-title":"Successful use of rivaroxaban in inferior vena cava thrombosis provoked by multiple traumatic injuries and surgeries: a case report","volume":"42","author":"K Kido","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijcard.2014.08.010","article-title":"Inferior vena cava filters in the United States: less is more","volume":"177","author":"M Alkhouli","year":"2014","journal-title":"Int J Cardiol"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ejvs.2017.06.025","article-title":"Outcomes of pharmacomechanical catheter-directed thrombolysis for acute and subacute inferior vena cava thrombosis: a retrospective evaluation in a single institution","volume":"54","author":"K Ye","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1160\/TH13-11-0938","article-title":"Evidence and clinical judgment: vena cava filters","volume":"111","author":"D Imberti","year":"2014","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1538-7836.2008.03002.x","article-title":"Determinants of health-related quality of life during the 2 years following deep vein thrombosis","volume":"6","author":"S R Kahn","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref32","first-page":"472","article-title":"Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)","volume":"116","author":"N Kucher","year":"2016","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/0971-3026.161436","article-title":"Endovascular treatment of thrombosed inferior vena cava filters: techniques and short-term outcomes","volume":"25","author":"M Arabi","year":"2015","journal-title":"Indian J Radiol Imaging"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejvs.2020.11.050","article-title":"Comparing safety and efficacy of rivaroxaban with warfarin for patients after successful stent placement for chronic iliofemoral occlusion: a retrospective single institution study","volume":"61","author":"X Zhang","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2018.10.027","article-title":"Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis","volume":"172","author":"T Sebastian","year":"2018","journal-title":"Thromb Res"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1733924.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T23:58:58Z","timestamp":1656633538000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1733924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":35,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,6,30]]},"published-print":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1733924","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]}}}